A Life-Saving therapy to treat a Fatal-Genetic disease

Life-Saving therapy for Fatal-Genetic disease

0
88

Zolgensma, the newly approved drug by the Food and Drug Administration, is now possible to treat and heal children with spinal muscular atrophy. The concave factor is that life-saving therapy will cost $2 million.

You can short the spinal muscular atrophy by calling it SMA.  It has turned into a podium to elaborate how costly the drug is! But, the parents of the affected children are considering it an angel or ‘godsend.’ Spinal Muscular Atrophy or SMA successfully adds at least one in 11,000 babies. The disease is fatal, and that is why an organization is completely dedicated to finding its cure and reason for the disease to occur.

According to the National Institute of Neurological Disorders and stroke, babies diagnosed with Spinal Muscular Atrophy (SMA) from the mother’s womb, the nerve cells present in the spinal cord and brain stem that co-ordinate and controls the muscles for breathing, speaking, walking and swallowing are destroyed. This condition continues as the child grows. With the increase in body mass of the child, the disease progress and weaken the muscle and atrophy. Like the baby of Almeida, who was five months pregnant when doctors communicated to her that she was likely to give birth to a baby suffering from SMA. The baby would not be able to survive for one year also was what the doctor said. Eventually, the baby lost the ability to breathe, eat, or even walk.

It was Nicole Almeida who put her serious motherhood in search of the roots of SMA. She did not want to give up on her baby. She went on carving out therapies and clinical trials for the baby. In a video, Nicole saw that a pig dragging its feet was cured with a single dose of gene therapy. She took the idea and was consoled when applied to her baby. The entire therapy turned out to be a miracle. The little boy is now fit to fine with health and happiness.

The therapy, Zolgensma holds the highest price tag for even a single dose of a drug. The maker of Zolgensma, Vas Narasimhan, and the Chief Executive Officer (CEO) of Novartis affirmed the reason saying that the cost of the drug is justified to the seriousness of the diseases. He even added that the latest cost of care is just 50% of what it should cost for children over ten years of age.

It is seen that the therapy is a boon because whatever the condition of SMA would be growing, Zolgensma has reacted positively, and every patient has shown results of the cure which has received it. Narasimhan said that he had 15 children on the mark to treat the drug with. Every one of the 15 children is doing well and good today.

The cost is nothing to the cure Zolgensma is contributing to treating the affected children of SMA. Doctors are in the tank of compliment that these healed children are developing normally. They will serve to be very bright children. This is a second opportunity for them to start their lives over again when they could not walk and eat.

The insurance companies are expected to cover the cost of the treatment. Nicole Almeida, in an interview with the outlet, said that nothing is comparable with the price of a life of a human. Every parent will find a way to save their kid, and Zolgensma is one of them.

LEAVE A REPLY

Please enter your comment!
Please enter your name here